CoChat
Sign Up
Cited by 466Glioma Diagnosis and TreatmentLung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

Haas-Kogan, Daphne A., Prados, Michael D., Tihan, Tarik, Eberhard, David A., Jelluma, Nannette, Arvold, Nils D., Baumber, Rachel, Lamborn, Kathleen R. +4 more·2005·JNCI Journal of the National Cancer Institute
DOI 10.1093/jnci/dji161
Open this paper in CoChat — free account

Abstract

BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (also known as Tarceva or OSI-774) has shown promising response rates in malignant gliomas. We investigated the association between expression of EGFR and downstream signaling components and the response of malignant gliomas to erlotinib in a phase I trial of erlotinib administered either alone or with the alkylating agent temozolomide. METHODS: Expression of EGFR and ligand-independent EGFRvIII mutant proteins and of phosphorylated protein kinase B (PKB)/Akt in specimens from glioma patients were assessed by immunohistochemistry. EGFR gene amplification was evaluated by fluorescence in situ hybridization. Mutations in PTEN and EGFR were assessed by polymerase chain reaction amplification and sequencing. Response was evaluated by sequential magnetic resonance imaging every 2 months. The Cochran-Mantel-Haenzel test was used to assess associations between biomarker status and response. All statistical tests were two-sided. RESULTS: Of 41 glioma patients, eight responded to treatment. Response to erlotinib was associated with EGFR expression (P = .07) and EGFR amplification (P = .08). These associations were stronger and statistically significant among the 29 patients initially diagnosed with glioblastoma multiforme (P = .03 and P = .02, respectively). Among six responders with sufficient tumor tissue, none had EGFRvIII mutations. None of the 22 tumors with high levels of phosphorylated PKB/Akt responded to erlotinib treatment, whereas eight of the 18 tumors with low levels of phosphorylated PKB/Akt responded to erlotinib treatment (P < .001). The level of phosphorylated PKB/Akt was also associated with time to progression (P < .001). CONCLUSIONS: Among glioma patients, those with glioblastoma multiforme tumors who have high levels of EGFR expression and low levels of phosphorylated PKB/Akt had better response to erlotinib treatment than those with low levels of EGFR expression and high levels of phosphorylated PKB/Akt.

Integrity signals

Registry

Crossref · 10.1093/jnci/dji161

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The EGFR inhibitors gefitinib and erlotinib have failed to demonstrate efficacy in GBM, largely as a consequence of persistent PI3K signaling due to PTEN loss and/or coactivation of other receptor tyrosine kinases.

    “Despite the compelling nature of EGFR as a drug target in GBM, the EGFR inhibitors gefitinib and erlotinib have failed to demonstrate efficacy (9–11), in large part as a consequence of persistent PI3K signaling due to PTEN loss and/or coactivation of other receptor tyrosine kinases (9, 10, 12).”

    From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [10]

  • Clinical evidence suggests that the presence of EGFRvIII can predict clinical responses of GBMs to the EGFR TKIs gefitinib and erlotinib.

    “There is clinical evidence suggesting that the presence of EGFRvIII can predict clinical responses of GBMs to the EGFR TKIs gefitinib and erlotinib (Haas-Kogan et al., 2005; Mellinghoff et al., 2005).”

    From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Haas-Kogan et al., 2005

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., Berger, M. S., & Stokoe, D.
Affiliations
University of California, San Francisco (US)
Corresponding author
Haas-Kogan, Daphne A.
ORCID
Venue
JNCI Journal of the National Cancer Institute
Publisher
Oxford University Press (OUP)
Published
2005-06-15
Volume
97
Issue
12
Pages
880-887
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
DOI
10.1093/jnci/dji161
OpenAlex
W2104743043
Cited by
465
References
37
Citations by year
2026: 3 · 2025: 2 · 2024: 4 · 2023: 8 · 2022: 4 · 2021: 4 · 2020: 9 · 2019: 5 · 2018: 7 · 2017: 13 · 2016: 6 · 2015: 17 · 2014: 24 · 2013: 27 · 2012: 34
FWCI
22.18
Type
journal article
Language
en
Open access
closed
Locations
  • JNCI Journal of the National Cancer Institute (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5m01rr000079-42)
  • National Cancer Institute (P50CA097257)
  • National Institute of Neurological Disorders and Stroke (P01NS042927, P01 NS42927)
  • National Center for Research Resources (M01 RR-00079)
Topics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
erlotinib, EGFR tyrosine kinase inhibitors, high-grade glioma, glioblastoma, EGFR amplification, EGFRvIII, Akt phosphorylation, Akt, temozolomide, predictive biomarkers, treatment response, PTEN mutation, time to progression
MeSH terms
Erlotinib Hydrochloride, Temozolomide, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Dacarbazine, Drug Administration Schedule, Female, Glioma, Humans, Immunohistochemistry, Male, Middle Aged, Mutation, Phosphoric Monoester Hydrolases, Phosphorylation, Proto-Oncogene Proteins, Quinazolines, Supratentorial Neoplasms, Protein Serine-Threonine Kinases, In Situ Hybridization, Fluorescence, Drug Resistance, Neoplasm, Area Under Curve, Tumor Suppressor Proteins, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review